The Inflation Reduction Act was signed into law on August 16, 2022, and the debate over its Medicare-related benefits and impact on the prescription drug market has been raging ever since.
This access and Medicare’s success are now under threat because of price-setting policies, including the ones contained in the Inflation Reduction Act’s (IRA) new Medicare “negotiation” program.